1. PharmaCyte expects that it will get funding for both pancreatic cancer and for diabetes. Once the company submits its IND and the FDA gives PharmaCyte the go-ahead to proceed with its clinical trial, then the funding sources that PharmaCyte has met with and is continuing to meet with can commit. Without an approved clinical trial, it doesn’t make much sense for any entity to commit millions of dollars yet.
As PharmaCyte moves further along with its diabetes program, the company fully expects to receive funding. Also, keep in mind that PharmaCyte can pay for patients as they are enrolled into the pancreatic cancer clinical trial. The company does not have to pay for the full trial up front or in one lump sum. If the company enrolls 10 patients, it can pay for those 10 patients.
2. TD2 had a representative speaking at the company's ASCO presentation in Chicago, which is available on the company’s website. At this time, both PharmaCyte and TD2 are extremely busy preparing to submit the IND and preparing for a pivotal trial, so additional Q&A articles with TD2 regarding the IND are not currently being written.
3. With all of the work that PharmaCyte has before it, a conference call has not been planned. Once the IND is submitted, the company would likely be in a much better position to host a shareholder call.
Thank you again for your email and for your interest in PharmaCyte.
News 
Market Data 
Discover 
